In a significant boost to its consumer health portfolio, Procter & Gamble (P&G) has concluded its €3.4 billion acquisition of German pharmaceutical giant Merck’s consumer health business. This move, first announced in April 2018, aims to elevate P&G’s position in the global over-the-counter (OTC) health market, adding extensive geographical scale and expanding its presence across […]
Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination with Eli Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum chemotherapy. This approval specifically targets the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults who do not […]
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ALKS 4230 in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab). This trial aims to explore the potential of this combination therapy in treating advanced solid tumors. ALKS 4230 is an […]
In a significant development for cancer treatment, Eisai and Merck have announced that the U.S. Food and Drug Administration (FDA) has approved Lenvima (lenvatinib) for the first-line treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer in adults. This approval marks a pivotal advance, offering a new treatment option for patients […]
Vyriad, a US-based biotech company, has partnered with Germany’s Merck to initiate a Phase 1 clinical trial targeting metastatic colorectal cancer. This trial explores the combined potential of Vyriad’s Voyager-V1 and Merck’s Bavencio (avelumab), offering a new approach to immuno-oncology treatment. Voyager-V1, developed by Vyriad, is an oncolytic virotherapy employing a bullet-shaped, negative-sense RNA virus […]
Procter & Gamble (P&G), a leading US consumer goods company, has finalized a deal to acquire the consumer health business of German pharmaceutical company Merck for approximately €3.4 billion ($4.2 billion). This all-cash transaction marks a significant expansion of P&G’s consumer health division by incorporating a range of over-the-counter (OTC) products from Merck. Expanding P&G’s […]
Significant Acquisition in Pharma Industry: US pharmaceutical giant Merck has announced a definitive agreement to acquire Viralytics, an Australian biotech company, for AUD 502 million (approximately $394 million). This acquisition is set to significantly enhance Merck’s portfolio in the burgeoning field of immuno-oncology. Strategic Expansion of Immuno-Oncology Pipeline: Through this acquisition, Merck aims to expand […]
Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease.
The US Food and Drug Administration (FDA) has granted approval to Merck’s cancer immunotherapy, Keytruda (pembrolizumab), in combination with chemotherapy, as a first-line treatment option for patients with advanced lung cancer who have not previously been treated with other medicines. This approval marks a pivotal development in the battle against metastatic non-squamous non-small cell lung […]